Department of Pharmacology

Istock image of neurons in the brain
January 8, 2018

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

By Bill Snyder
December 7, 2017

Lindsley honored by Pharmaceutical Society of Japan

Craig Lindsley, PhD, the William K. Warren Jr. Professor of Medicine at Vanderbilt, is the 2018 recipient of the Sato Memorial International Award of the Pharmaceutical Society of Japan.

By Bill Snyder
autism concept: puzzle
November 16, 2017

Study may point to new treatment approach for ASD

Using sophisticated genome mining and gene manipulation techniques, researchers at Vanderbilt University Medical Center (VUMC) have solved a mystery that could lead to a new treatment approach for autism spectrum disorder (ASD).

By Bill Snyder
October 19, 2017

McGill University honors Roden’s research career

Dan Roden, M.D., Senior Vice President for Personalized Medicine at Vanderbilt University Medical Center (VUMC), was named to receive the 2017 Medicine Alumni Global Lifetime Achievement Award by the Faculty of Medicine of his alma mater, McGill University.

By Doug Campbell
September 21, 2017

Grant supports Oates’ research on acetaminophen and stroke

John Oates, M.D., a pioneering clinical pharmacologist at Vanderbilt University Medical Center (VUMC), has been awarded a one-year, $20,000 grant from the Brain Aneurysm Foundation to support studies of the stroke-reducing potential of acetaminophen.

By Bill Snyder
September 21, 2017

University of Kansas honors Lindsley’s pharmacology research

Craig Lindsley, Ph.D., co-director of the Vanderbilt Center for Neuroscience Drug Discovery, has been honored by the University of Kansas with the 2018 Edward E. Smissman Lectureship for his outstanding contributions to the fields of medicinal chemistry and molecular pharmacology.

By Bill Snyder
September 20, 2017

Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs

An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.
By VUMC News and Communications
September 15, 2017

Inhibiting obesity

An enzyme in the gut – NAPE-PLD – is required for the action of signaling molecules that reduce food intake and weight gain.
By Leigh MacMillan
August 7, 2017

Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
By Bill Snyder
July 26, 2017

Vanderbilt mourns loss of pharmacologist H. Alex Brown

H. Alex Brown, Ph.D., the Bixler-Johnson-Mayes Professor in the Department of Pharmacology at Vanderbilt University School of Medicine, died from cancer Tuesday, July 25, at his home. He was 56.
By Bill Snyder
July 3, 2017

NOTCH1 role in heart development

The identification of a genetic culprit for hypoplastic left heart syndrome could lead to new treatments for the condition.
By VUMC News and Communications
June 30, 2017

Cytokine linked to blindness

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered.
By VUMC News and Communications
June 15, 2017

Pharmacology top teacher

Ronald Emeson, Ph.D., is a three-time winner of the Teacher of the Year Award presented by graduate students in the Department of Pharmacology
By VUMC News and Communications
1 … 5 6 7 8 9 … 14